Area Editoriale

Gli immunosoppressori riducono l’immunogenicità dell’infliximab ?

14 febbraio 2007 | IBD

Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk? Hanauer SB. Gut. 2007 Sep;56(9):1181-3.

Since the introduction of infliximab to treat Crohn's disease, combination therapy with immunosuppressants has reduced immunogenicity, without impacting efficacy. The availability of novel anti-TNF agents and potential combined toxicities question the risk/benefit of combination therapies.
Leggi l’articolo